An FDA advisory panel concluded that the limited benefits of Serenity Pharmaceuticals LLC/Allergan PLC’s desmopressin nasal spray for nocturia – essentially cutting down nighttime trips to the bathroom by a few times per week – outweigh its risks and recommended approval.
However, many members advised FDA to limit the indication to treatment of nocturnal polyuria, which is present in about 80%...




